You just read:

Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Oct 04, 2018, 07:47 ET